Calorie restriction increases Fas/Fas-ligand expression and apoptosis in murine splenic lymphocytes  by Reddy Avula, C.P et al.
Calorie restriction increases Fas/Fas-ligand expression and apoptosis in
murine splenic lymphocytes
C.P. Reddy Avula, A. Muthukumar, G. Fernandes*
Division of Clinical Immunology, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio,
TX 78229-3900, USA
Received 29 July 1999; received in revised form 19 August 1999
Abstract One-month-old male ICR mice were fed a nutrition-
ally adequate, semipurified diet, either ad libitum (AL) or calorie
restricted (CR) (40% less food) for 6 months and were killed to
obtain spleens. Flow cytometric analysis revealed increased
proportions of both CD4+ and CD8+ T cells in CR-fed mice
compared to AL-fed mice. The T cell subsets of CR-fed mice
were also found to have higher levels of plasma membrane Fas
receptor expression. Similarly, Fas-ligand (Fas-L) expression
was higher in anti-CD3-stimulated CD4+ and CD8+ T cells. CR-
fed mice also had increased numbers of annexin V-positive CD4+
and CD8+ T cells in stimulated splenic lymphocytes suggesting
an increased potential for apoptosis. Fas and Fas-L gene
expression in splenic lymphocytes, which correlated closely with
the observed increased rate of apoptosis, was significantly
increased in CR-fed mice compared to AL-fed mice. In
conclusion, these results indicate that CR increases the expres-
sion of Fas and Fas-L which may contribute to the known
beneficial effects of CR such as prolongation of life span by
activating chronic physiologically mediated apoptosis.
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1. Introduction
One third of all cancer-related deaths, world wide, are
closely linked to dietary factors [1]. Particularly, excess caloric
intake appears to be the most important causative factor in
promoting obesity and various malignancies. In several rodent
models, overall dietary or caloric restriction alone is found to
decrease tumor incidence [2^4]. Moderate calorie restriction
(CR) (40% less food intake) is well established in the preven-
tion and/or delay of onset of age-associated, life-shortening
diseases (e.g. breast cancer and kidney disease) in rodents
[5^7]. In autoimmune-susceptible mice, CR is found to delay
the loss of immune function and prolong the life span [6,7].
CR was also found to lower the incidence of breast and liver
tumors by increasing apoptosis and by increasing antioxidant
enzyme mRNA thereby decreasing the proliferative rate of
tumor cells [8^10].
Apoptosis (programmed cell death) plays a central role in
embryogenesis, morphogenesis, and immune cell regulation
and is likely to act as a defense mechanism against infectious
diseases and also during aging. Apart from its role in normal
cell regulation, apoptosis is observed in a variety of patholog-
ical processes such as cancer, neurodegenerative disorders,
and autoimmune diseases (e.g. arthritis and systemic lupus
erythematosus) [11^13].
Intracellular pathways leading to apoptosis are as complex
as those involved in cellular growth and di¡erentiation [14].
Impaired growth signaling pathways, including apoptotic sig-
nal transduction, may lead to the onset of a variety of diseases
[14]. Apoptosis is closely regulated by a number of gene prod-
ucts that either promote cell death or extend cell survival
[15,16].
Fas/APO-1 (CD95) is a cell surface receptor of the tumor
necrosis factor (TNF) receptor superfamily that mediates T
and B lymphocyte apoptosis [17]. Fas-ligand (Fas-L), ex-
pressed predominantly on activated T lymphocytes [18], me-
diates cell death by cross-linking to the Fas receptor [18,19].
Earlier studies, including our own, showed that CR modulates
lymphocyte subsets and increases apoptosis [20,21]. Involve-
ment of Fas and Fas-L in both peripheral lymphoid cell death
and lymphoid organ development is well-established [22]. Ac-
tivation-induced apoptosis is a primary mechanism for the
down regulation of an immune response leading to immune
homeostasis and defective T cell speci¢city [23].
The present investigation was aimed at determining the ef-
fect of CR on induction and expression of Fas and Fas-L, and
the rate of apoptosis in splenic lymphocytes of ICR mice.
2. Materials and methods
2.1. Materials
Brefeldin A, ionomycin, and phytohemagglutinin (PMA) were ob-
tained from Sigma Chemical Co. (St. Louis, MO, USA). Dexametha-
sone, annexin V, propidium iodide (PI) and all FITC and PE labeled
antibodies and antibody isotype controls were purchased from Phar-
mingen (San Diego, CA, USA). All other chemicals (analytical grade)
were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
2.2. Animals
Outbred, weight-matched, male ICR mice (albino, weanling mice
obtained from Taconic, NY, USA) at 4 weeks of age were grouped
and housed, ¢ve mice per cage in a temperature-controlled room at
24‡C and maintained on a 12:12 h dark-light cycle, in the laboratory
animal care facility at the University of Texas Health Science Center
at San Antonio. Mice were fed a nutritionally adequate AIN76 for-
mula semi-puri¢ed diet containing 5% (w/w) corn oil (CO), either ad
libitum (AL) or 40% CR as described earlier [24]. Nutrient intake was
su⁄cient to prevent de¢ciency. The composition of the diet was 20%
casein, 50% dextrose, 15% starch, 5% cellulose, 5% corn oil, 3.5%
AIN salt mixture, 1% AIN vitamin mixture, 0.3% DL-methionine
and 0.2% choline chloride
After 28 weeks of feeding, mice were fasted overnight and given a
mild anesthesia. Peripheral blood was then collected by retro-orbital
bleeding, and mice were killed by cervical dislocation. Spleens were
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aseptically removed and placed in RPM1 1640 complete medium
(containing 10% heat inactivated FCS, 100 mM L-glutamine, 100 U/
ml penicillin, 100 Wg/ml streptomycin and 10 WM 2-mercaptoethanol
(ME)). Serum was separated by centrifuging the whole blood at
1000Ug for 15 min and analyzed immediately. All procedures were
approved by the Institutional Animal Care and Use Committee.
2.3. Splenocyte preparation
Single cell suspensions were prepared by disrupting the spleen be-
tween frosted glass slides in RPMI 1640 medium with 2% heat-inacti-
vated fetal calf serum. After a 5 min centrifugation at 100Ug to
separate cells from debris, the cells were washed twice in RPMI me-
dium [25]. Spleen lymphocytes were puri¢ed by layering over lympho-
lyte (Cedarlane Labs. Lit., Hornby, Ont., Canada), centrifuging at
1000 rpm for 15 min at 22‡C, then washing twice in RPMI 1640
complete medium. Cells were counted and viability was determined
by trypan blue exclusion.
2.4. Quanti¢cation of apoptosis and necrosis
Lymphocytes, 1U106, were incubated for 24 h in RPMI complete
medium with or without 2 Wg anti-CD3 monoclonal antibody (mAb)
in a ¢nal volume of 1 ml in a 5% CO2-humidi¢ed incubator at 37‡ C.
After incubation, cells were washed twice with binding bu¡er (10 mM
HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), resuspended
in 200 Wl binding bu¡er in the presence of 0.2 Wg FITC-annexin V and
2 Wg PI then incubated in the dark for 10 min [26]. Annexin V and PI
staining, as indicators of apoptosis and necrosis respectively, were
measured with the FACScan (Becton Dickinson) using the Cell Quest
software as described earlier [27].
2.5. Flow cytometric analysis of Fas, Fas-L and annexin V staining of
splenocyte subsets
Cells were washed with isotonic NaCl/phosphate bu¡er containing
0.5% bovine serum albumin (BSA) and 0.2% NaN3 (wash bu¡er).
Cells (1U106) were incubated with 0.1 Wg of Fc block at room tem-
perature for 10 min. After two washes in wash bu¡er, 1U105 cells in
200 Wl wash bu¡er were incubated at 4‡C for 30 min with 2 Wl of one
of the following pairs of monoclonal antibodies: anti-CD4-PE/anti-
Fas-FITC or anti-CD8-PE/anti-Fas-FITC. An isotype control for
anti-Fas-FITC was used in all experiments.
Because Fas-L is expressed on activated T cells, splenocytes (1U06
cells) were activated in the presence of soluble anti-CD3 mAb (2 Wg/
ml) for 24 h and after washing, the cells were further stimulated with
brefeldin A, PMA and ionomycin (2 Wg, 10 ng and 1 Wg/ml respec-
tively) for 4 h in a humidi¢ed atmosphere at 37‡C with 5% CO2. Cells
were blocked, then cell aliquots incubated for 30 min with anti-CD4
or -CD8 FITC-labeled mAb as described above. Cells were then ¢xed
with 200 Wl of 1% paraformaldehyde in wash bu¡er for 15 min with
continuous shaking at room temperature. Lymphocytes were washed
with wash bu¡er, and then permeabilized by suspending in 200 Wl of
0.33% saponin at 4‡C for 45 min. Permeabilized cells were washed and
stained with anti Fas-L-PE and isotype anti-Fas-PE in 200 Wl wash
bu¡er at 4‡C for 45 min.
2.6. Annexin V staining of splenocyte subsets
Cells incubated with medium alone or with anti-CD3 were blocked
with Fc receptor and cell aliquots incubated for 30 min with anti-
CD4- or CD8-PE-labeled mAb as described above. Cells were washed
twice with binding bu¡er (10 mM HEPES/NaOH, pH 7.4, 140 mM
NaCl, 2.5 mM CaCl2), then incubated with 0.2 Wg of annexin V-FITC
for 15 min in the dark. Cellular £uorescence was analyzed by £ow
cytometry (Becton Dickinson FACScan £ow cytometer) using the Cell
Quest program. (All antibodies were purchased from Pharmingen,
San Diego, CA, USA.)
2.7. Reverse transcription (RT)-PCR of Fas and Fas-L mRNA
Cellular RNA was isolated from 3U106 cells using Trizole reagent
(Gibco BRL, Life Technologies Grand Island, NY, USA) as described
by the manufacturer. Reverse transcription of 1 Wg RNA was per-
formed using oligo-dT, 10 mM dNTPs, 20 units RNase inhibitor and
reverse transcriptase (Gibco BRL, Life Technologies) in a total vol-
ume of 20 Wl. PCR was performed in a mixture containing 3 Wl cDNA
and 1 WM primers of Fas or Fas-L (CLP continental Lab products
Cat. Nos. 5245.M and 5246.M). Ampli¢cation was performed using
Taq-polymerase (Promega, Madison, WI, USA) with one initial de-
naturation cycle for 2 min at 94‡C, 2 min at 60‡C; 25 cycles for 1 min
at 94‡C, 1 min at 60‡C, and 2 min at 72‡C; and a ¢nal extension
phase consisting of one cycle of 2 min at 72‡C. The GAPDH (3P
primer TCC ACC ACC CTG TTG CTG TA and 5P primer ACC
ACA GTC CAT GCC ATC AC) housekeeping gene was used as a
control. PCR products were separated by electrophoresis on a 1.5%
agarose gel containing ethidium bromide and visualized by UV light
illumination. Band density was measured using an Alpha Imager 2000
(Alpha Innotec Corporation).
2.8. Statistical analysis
The data shown are the mean þ S.E.M. of ¢ve individual values.
Data were statistically analyzed using the Student’s t-test and
P6 0.05 was considered signi¢cant.
3. Results and discussion
In the present study, mice on the CR diet gained signi¢-
cantly less (51%) body weight (23 þ 0.5 vs. 47.2 þ 0.44), com-
pared to mice on the AL diet. Similar results without any
malnourishment were also observed in earlier studies [21,28].
The in£uence of CR on lymphocyte subsets is summarized
in Fig. 1. Similar to previous reports [20,21], the present study
also showed that CR mice maintain a signi¢cantly higher
percentage of CD4 and CD8 splenocytes (15 and 35% re-
spectively), compared to AL mice. Further, CR also signi¢-
cantly decreased CD19 splenocytes (22%). Decreased B lym-
phocytes in CR can contribute to lowering the incidence of B
cell lymphoma in autoimmune diseases [29].
Interestingly, CR signi¢cantly modi¢ed the phenotypic ex-
pression of Fas and Fas-L in activated T lymphocytes (Figs. 2
and 3). Two-color £ow cytometric analysis showed that the
overall percentages of Fas cells in CD4 and CD8 lympho-
cytes of CR mice were increased by 13 and 24% respectively,
compared to that of AL mice. Similarly, the percentages of
Fas-L cells in CD4 and CD8 lymphocytes of CR mice
were increased by 38.8 and 39.6% respectively, compared to
AL-fed mice.
The main function of Fas antigen is to trigger the induction
of apoptosis [30]. The Fas receptor was ¢rst described as a
molecule expressed on the surface of certain cell lines, which
could mediate apoptosis when triggered by a speci¢c mono-
clonal antibody [31]. The Fas system plays an important role
in modulating B and T lymphocyte development and their
function [32]. Further, binding of Fas-L to Fas antigen results
in intracellular signals leading to apoptosis [30]. Fas-L is one
Fig. 1. E¡ect of CR and AL on splenocyte subsets. Values are
mean þ S.E.M. of ¢ve individual values. aStatistically signi¢cant at
P6 0.05.
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of the major e¡ectors of CD8 cytotoxic lymphocytes and is
involved in the establishment of peripheral tolerance [33] and
the activation induced cell death of lymphocytes [19,34]. It is
well established that apoptosis is a distinct form of cell death
that is essential to the regulation of the immune system. In
this study, apoptosis was analyzed by £ow cytometry, using
both annexin V and PI staining. Because phosphatidylserine is
exclusively located in the cell membrane lea£ets that face the
cytosol in live cells, the surface expression of phosphatidylser-
ine is a feature of apoptosis, and it occurs before the loss of
membrane integrity [35]. It is also known that early apoptotic
cells bind annexin V, a Ca2-dependent phospholipid binding
protein with high a⁄nity for phosphatidylserine, but exclude
PI and can therefore be speci¢cally detected and quanti¢ed by
FACS analysis [36]. Annexin V staining for apoptosis was
signi¢cantly increased in both CD4 and CD8 cells of CR
mice incubated with anti-CD3 (67 and 40%, respectively), or
medium alone (49.9 and 31.5%, respectively) compared to AL-
fed mice (Fig. 4). Spontaneous, as well as anti-CD3 mAb-
induced apoptosis in total lymphocytes was also increased,
by 39.3 and 60.7% respectively, in CR mice compared to
AL-fed mice (Fig. 5). However, CR did not change the ne-
crotic cell population, as measured by double staining with
annexin V and PI, which may indicate advanced apoptotic
cells rather than necrotic cells (Fig. 6). Previous studies also
showed a signi¢cantly increased apoptosis in CR-fed autoim-
mune-prone and -resistant strains of mice [21,37].
Increased Fas expression on CD4 and CD8 cells in CR-
fed mice is most likely physiologically signi¢cant. In this study
we have demonstrated that increased expression of Fas and
Fas-L on T lymphocytes is directly correlated with increased
apoptosis in CD4 and CD8 cells from CR mouse spleens.
Defects in the Fas/Fas-L pathway have been shown to result
in autoimmune disease [23]. Defective antigen-mediated cell
death can contribute to an increased number of autoreactive
cells [38]. Loss of apoptotic function due to mutations in
murine Fas-L (gld) or Fas (lpr) or human Fas or Fas-L leads
to lymphoproliferation, lymphadenopathy and autoimmune
disease [39]. The physiological regulation of programmed
cell death is essential for removal of potentially autoreactive
lymphocytes and prevention of an autoimmune response. It is
now widely accepted that apoptosis plays an important role in
the selection of immature thymocytes to maintain functionally
active peripheral T lymphocytes [40]. In addition, B lympho-
cytes are thought to die by apoptosis during their develop-
ment in the bone marrow [41]. Results presented here suggest
that CR enhances the sensitivity of splenocytes to activation-
Fig. 2. E¡ect of CR and AL on phenotype expression of Fas on
splenocyte subsets. Values are mean þ S.E.M. of ¢ve individual val-
ues. aStatistically signi¢cant at P6 0.05.
Fig. 3. E¡ect of CR and AL on phenotype expression of Fas-L on
splenocyte subsets. Values are mean þ S.E.M. of ¢ve individual val-
ues. aStatistically signi¢cant at P6 0.05.
Fig. 4. E¡ect of CR and AL on annexin V binding to splenocyte
subsets. Splenocytes were incubated for 24 h in (A) medium alone
or (B) medium with anti-CD3, as described in Section 2. Values are
mean þ S.E.M. of ¢ve individual values. aStatistically signi¢cant at
P6 0.05.
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induced cell death leading to elimination of hyperreactive lym-
phocytes. Further, there is increasing evidence that alteration
in cancer cell sensitivity to Fas-mediated apoptosis is a key
factor in controlling tumor progression [42]. Perturbations in
the Fas/Fas-L cell death pathway also appear to be important
in determining the viability of transformed cells [43].
The role of CR in increasing apoptosis in other organs,
such as liver, has also been recently described [10,44]. Further,
CR was shown to lower the incidence of hepatocarcinoma and
decrease the proliferation of murine hepatocytes. Decreased
carcinogenesis and tumor formation in CR-fed mice has been
suggested to be due to increased apoptosis [10]. This increase
in the intrinsic rate of apoptosis may contribute, in part, to
the decreased tumor incidence and increased life span ob-
served in CR rodents [37].
Dietary alterations are known to have a marked in£uence
on the expression of several genes. Diet or hormones, or their
metabolites, may cause coordinated changes in protein syn-
thesis and the abundance of mRNA, indicating that cellular
control is at the molecular level [45,46]. We analyzed the ex-
pression of Fas- and Fas-L-bearing cellular mRNA by RT-
PCR in stimulated and unstimulated freshly isolated spleno-
cytes (Fig. 7A) and found that Fas and Fas-L were signi¢-
cantly increased in CR-fed mice. Analysis of the Fas and Fas-
L/GAPDH mRNA product ratios indicates that Fas and Fas-
L expression is signi¢cantly increased by 12.5 and 32% respec-
tively, in the splenocytes of CR mice, compared to AL mice
(Fig. 7B).
Earlier ¢ndings from our laboratory showed decreased
mRNA expression of proin£ammatory cytokines (interleu-
kin-6, tumor nerosis factor K), and increased expression of
the anti-in£ammatory cytokine, tumor growth factor L in
CR mouse spleen cells [7], indicating that CR modulates the
expression of various cytokines and growth factors. We have
also reported that CR signi¢cantly inhibited the development
of mammary tumors and altered the expression of both cyto-
kines and oncogenes, particularly elevation of p53, which was
noted in tumor tissues of CR-fed mice. We hypothesized that
elevation of p53 by CR may contribute to increased apoptosis
of tumor cells. Indeed, 80% of AL-fed mice developed breast
tumors, whereas only 30% of CR-fed mice had visible breast
tumors. Furthermore, in the same breast tumor tissues, CR
increased free radical scavenging enzyme expression [4].
In conclusion, our results indicate that CR increases the
expression of apoptotic mediators such as Fas and Fas-L in
splenocytes which may facilitate increased cell death and
Fig. 5. E¡ect of CR and AL on necrosis and apoptosis in spleno-
cytes. Splenocytes were incubated for 24 h in medium alone or me-
dium with anti-CD3, as described in Section 2. Values are mean þ
S.E.M. of ¢ve individual values. aStatistically signi¢cant at P6 0.05.
Fig. 6. A representative contour plot (out of ¢ve) showing the e¡ect
of CR on apoptosis and necrosis. Annexin V (lower right quad-
rant) indicates apoptotic and annexin V and PI (upper right
quadrant) indicates necrotic (advanced apoptosis) populations. Cells
were incubated either with medium (A and B) or with medium with
anti-CD3 (C and D). A and C: AL; B and D: CR.
Fig. 7. A: Ratio of Fas and Fas-L/GAPDH mRNA in spleens of
AL and CR mice. Values are mean þ S.E.M. of four individual val-
ues. aStatistically signi¢cant at P6 0.05. B: Representative gel of
Fas, Fas-L and GAPDH mRNA in spleen of AL and CR mice.
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thereby prevent accumulation of autoreactive immune cells. It
thus appears that by enhancing the cell death potential, CR is
likely to play a major role in controlling cancer and auto-
immune diseases and thereby facilitate the prolongation of
the life span [47,48].
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